S-1/A: Cartesian Therapeutics Files for Resale of 6.5 Million Shares Following Merger and Private Placement

Cartesian Therapeutics is registering for the resale of up to 6.5 million shares of its common stock by selling stockholders after a recent merger and private placement.

Summary

• Cartesian Therapeutics has filed a registration statement for the resale of up to 6,501,150 shares of its common stock.
• These shares are being offered by selling stockholders, which include institutional and accredited investors who acquired the shares through a private placement that closed on July 3, 2024.
• The shares consist of (i) 3,563,247 shares of Common Stock and (ii) 2,937,903 shares of Common Stock issuable upon the conversion of 2,937,903 shares of Series B Preferred Stock.
• The company will not receive any proceeds from the sale of these shares.
• The selling stockholders may sell the shares through various methods, including on national securities exchanges, in the over-the-counter market, or in privately negotiated transactions.
• The last reported sale price for Cartesian Therapeutics' Common Stock on September 19, 2024, was $16.54 per share.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily focused on the mechanics of the share resale. The lack of company commentary or forward-looking statements makes it difficult to assess sentiment beyond a neutral stance.

Risks

• An investment in the company's securities involves a high degree of risk, as detailed in the 'Risk Factors' section of the prospectus.
• The selling stockholders may sell any, all, or none of the securities offered by this prospectus, and the company does not know when or in what amount the selling stockholders may sell their Resale Shares hereunder following the effective date of the registration statement of which this prospectus forms a part.

Future Outlook

The selling stockholders will determine when and how they will dispose of the shares of Common Stock and shares of Common Stock issuable upon conversion of Series B Preferred Stock registered under this prospectus for resale.

Industry Context

This announcement is typical for biotechnology companies that have recently completed a merger or private placement, allowing early investors to liquidate their positions.

Stakeholder Impact

• The resale of shares by selling stockholders could potentially impact the share price of Cartesian Therapeutics.
• Existing shareholders may experience dilution if the Series B Preferred Stock is converted into Common Stock.

Next Steps

• The selling stockholders may sell the Resale Shares on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale, on the over-the-counter market, in one or more transactions otherwise than on these exchanges or systems, such as privately negotiated transactions, or using a combination of these methods, and at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices.

Key Dates

Keywords

common stock, resale, securities, private placement, selling stockholders, Cartesian Therapeutics, Series B Preferred Stock, conversion